Congress Materials – Myasthenia Gravis Foundation of America (MGFA 2025)
2025 Myasthenia Gravis Foundation of America | Oct 29 | San Francisco, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
An Analysis of Digital Conversations to Understand Patient Perceptions of the Dosing and Administration of Neonatal Fc Receptor Inhibitors for Treatment of Myasthenia Gravis
Andrew Gordon, Nolan Campbell, Caroline Brethenoux, Patrick Furey, Alex Lorenzo, Alyssa DeLuca, Rosario Alvarez, Laura Gonzalez, Zia Choudhry, Nikita Maniar
Assessment of Patient-Reported Outcomes from the Phase 3 Vivacity-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis
Elena Cortés Vicente, Sheryl Pease, Nida Imran, Kavita Gandhi, Maria Ait-Tihyaty, Ibrahim Turkoz, Geoffroy Coteur, Charlotte Gary, Zia Choudhry, Sindhu Ramchandran, John Vissing
Composite Response To Nipocalimab Based On Both Myasthenia Gravis Activity Of Daily Living And Quantitative Myasthenia Gravis Scores In Patients With Generalized Myasthenia Gravis
Said R. Beydoun, Maria Ait-Tihyaty, Ibrahim Turkoz, Kavita Gandhi, Sindhu Ramchandren
Design of a Digital Solution to Improve Myasthenia Gravis Patient Symptom Monitoring in Routine Clinical Care
Srikanth Muppidi, Joshua Alpers, Ashley EL Anderson, Nicholas Streicher, Ananda Vishnu Pandurangadu, Hari Jayaraman, Archit Gupta, Nolan Campbell, Zia Choudhry
Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab (EPIC): Study design and Rationale
Srikanth Muppidi, Andrea Corse, Heinz Wiendl, Ibrahim Turkoz, Ruben Faelens, Zia Choudhry, John J Sheehan, Maria Ait-Tihyaty, Nolan Campbell
Efficacy of Nipocalimab in Open-Label Extension in Patients Transitioned from Placebo: Results from Vivacity-MG3 Trial
Kristl G. Claeys, Maria Ait-Tihyaty, Kavita Gandhi, Ibrahim Turkoz, Zia Choudhry, Wim Noel, Charlotte Gary, Sindhu Ramchandren, Tuan Vu
Factors Associated with Exacerbations or Crises in Generalized Myasthenia Gravis
Kavita Grover, Kavita Gandhi, Martin Cloutier, Geoffroy Coteur, Nida Imran, Maryia Zhdanava, Antoine C. El Khoury, Porpong Boonmak, Anabelle Tardif-Samson, Yuxi Wang, Zia Choudhry, Nicholas J. Silvestri
Fatigue Assessed by Neuro-Quality of Life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalised Myasthenia Gravis
John Vissing, Kavita Gandhi, Sheryl Pease, Nida Imran, Maria Ait-Tihyaty, Ibrahim Turkoz, Geoffroy Coteur, Charlotte Gary, Zia Chaudhry, Sindhu Ramchandran
Hospital Resource Utilization Associated With Nipocalimab Versus Placebo: Post-Hoc Analysis Of The Vivacity-MG3 Trial In Generalized Myasthenia Gravis
John Vissing, Geoffroy Coteur, Ibrahim Turkoz, John Sheehan, Kavita Gandhi
Identifying Risk Factors for Exacerbation and Symptom Worsening—A Retrospective Cohort Study of Patients with Myasthenia Gravis in the United States
Zia Choudhry, Minjee Park, Pushpa Narayanaswami, Nizar Souayah, Raghav Govindarajan, Michael Kutch, Amaia Zurinaga Gutierrez, Aurélie Chekroun Martinot, Nolan Campbell, Richard Nowak
Insights Into Nipocalimab-Neonatal Fragment Crystallizable Receptor Structure (FcRn), Binding Affinity, and Inhibition of Immunoglobulin G Recycling: Comparison With Efgartigimod
Nilufer Seth, Rui Xu, Brian Stoveken, Matthew DuPrie, Samuel Sihapong, Traymon Beavers, Leona E. Ling, Maria Ait-Tihyaty, John J. Sheehan, Tuan Vu
Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results
Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Eriene Youssef, Panna Sanga, Ibrahim Turkoz, Yaowei Zhu, John Sheehan, Hong Sun
Mapping out the Patient Journey of Generalized Myasthenia Gravis: Insights and Challenges
Zia Choudhry, Louis Jackson, Nolan Campbell, Lisa Shea, Sindhu Ramchandren, Maria Ait-Tihyaty, Kelly G. Gwathmey, Kavita Grover, Bassam Malo
Nipocalimab Effect On Immunoglobulin G Subclasses In Patients With Generalized Myasthenia Gravis
Xia Li, Juan-José Pérez-Ruixo, Yaowei Zhu, Jocelyn H. Leu, John J. Sheehan, Ruben Faelens
Patient and Caregiver Experiences of Symptom Instability and Unpredictability from a Myasthenia Gravis Patient Engagement Research Council: A Generative AI-Assisted Analysis
Nicholas Streicher, OluYemisi Falope, Bruce West, Victor Wang, Rebecca Genin, Louis Jackson, Zia Choudhry, Kavita M. Grover
Population Pharmacokinetics And Pharmacodynamics Modeling Of Nipocalimab In Adolescents Aged 12 To Less Than 18 Years With Generalized Myasthenia Gravis
Yupeng Ren, Yaowei Zhu, Navin Goyal, Juan Jose Perez Ruixo, Ruben Faelens
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine and Anti-Virus Antibodies in Patients Treated with Nipocalimab in Vivacity-MG3 Study
Faye Yu, Eugene Myshkin, Sindhu Ramchandren, Ricardo Rojo Cella, Robert Edwards, Matthew J. Loza, Dessislava Dimitrova, Carolyn Cuff, Sheng Gao
Predicting Total Immunoglobulin G Change From Baseline When Switching From Efgartigimod to Nipocalimab
Martine Neyens, Yaowei Zhu, Nolan Campbell, John J. Sheehan, Ruben Faelens
Safety And Efficacy Results of Nipocalimab in Adolescents with Generalized Myasthenia Gravis During Active-Treatment and Long-term Extension Phases: VIBRANCE-MG Phase 2/3 Study
Jonathan Strober, Shawn Black, Marie Fitzgibbon, Saunder Bernes, Akiyuki Uzawa, Yasuhiro Kimoto, Keiko Ishigaki, Tuan Vu, Erin E. Neil Knierbein, Hideki Shimomura, Erik H. Niks, Dan Huang, Yaowei Zhu, Sindhu Ramchandren
Safety Profile of Nipocalimab, a New Neonatal Fragment Crystallizable Receptor Blocker in the Phase 3 VIVACITY Study
Hans Katzberg, Maria Ait-Tihyaty, Ibrahim Turkoz, Kavita Gandhi, Sindhu Ramchandren
Symptom Severity Assessment Using Quantitative Myasthenia Gravis Items and Domains in a 24-week, Phase 3 Study (Vivacity-MG3) of Nipocalimab in Generalized Myasthenia Gravis
Mazen M. Dimachkie, Constantine Farmakidis, Kavita Gandhi, Maria Ait-Tihyaty, Ibrahim Turkoz, Sheryl Pease, Zia Choudhry, Charlotte Gary, Antoine C. El Khoury, Sindhu Ramchandren
Treatment-Related Characteristics Among Younger Women With Generalized Myasthenia Gravis
Jacqueline Pesa, Louis Jackson, Alex Keenan, Nolan Campbell, Gregor Gibson, Joe Conyers, Neelam Goyal
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
